ProMIS Neurosciences (PMN)

Executive Summary

ProMIS Neurosciences is a clinical-stage biotechnology company developing novel therapeutics and diagnostics for neurodegenerative diseases, leveraging its proprietary EpiSelect™ computational discovery platform. The platform identifies and predicts toxic misfolded protein conformations implicated in diseases such as Alzheimer's, Parkinson's, and ALS, enabling the design of highly specific monoclonal antibodies. The company's lead product candidate, PMN310, is a monoclonal antibody targeting toxic amyloid-beta oligomers for Alzheimer's disease, currently in Phase 1 clinical trials. Additionally, ProMIS is advancing preclinical programs targeting misfolded TDP-43 in ALS and synuclein in Parkinson's, with a focus on disease-modifying therapies. The company's unique approach aims to address the root causes of neurodegeneration by selectively targeting pathological conformers while sparing normal proteins, potentially improving efficacy and safety. Financially, ProMIS is well-positioned with a strong intellectual property portfolio and strategic collaborations. With its differentiated platform and pipeline targeting high-unmet-need indications, ProMIS represents an attractive investment opportunity in the neurodegenerative space.

Upcoming Catalysts (preview)

• Q3 2026Phase 1 Data Readout for PMN310 in Alzheimer's Disease65% success
• Q1 2027IND Filing for Lead Antibody Targeting TDP-43 in ALS70% success
• H2 2026Strategic Partnership or Licensing Deal for EpiSelect Platform40% success